Aardvark Therapeutics (AARD)
Market Price (7/12/2026): $7.61 | Market Cap: $166.0 MilSector: Health Care | Industry: Biotechnology
Aardvark Therapeutics (AARD)
Market Price (7/12/2026): $7.61Market Cap: $166.0 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -55% Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Biopharmaceutical R&D, Targeted Therapies, Show more. | Weak multi-year price returns2Y Excs Rtn is -83%, 3Y Excs Rtn is -117% | Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -75 Mil Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -46% High stock price volatilityVol 12M is 121% |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -55% |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Biopharmaceutical R&D, Targeted Therapies, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -83%, 3Y Excs Rtn is -117% |
| Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -75 Mil |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -46% |
| High stock price volatilityVol 12M is 121% |
Qualitative Assessment
AI Analysis | Feedback
Updated on 7/12/2026
Aardvark Therapeutics (AARD) stock has gained about 100% since 3/31/2026 because of the following key factors:
1. Recovery from Heavily Oversold Conditions: Following substantial stock price declines, including a 56% drop in early March 2026 due to a voluntary pause of its lead ARD-101 Phase 3 trial and a further 32-34% plunge in mid-May 2026 after the U.S. Food and Drug Administration (FDA) issued a full clinical hold on ARD-101, Aardvark Therapeutics' shares likely became significantly oversold. This severe undervaluation attracted bargain hunters and prompted short covering, driving a sharp rebound from its low point around $3.59 in early June 2026 to approximately $7.60 by early July 2026.
2. Commitment to ARD-101 Program and Financial Stability: Despite the FDA clinical hold, Aardvark announced in mid-May 2026 its plans to unblind the accumulated clinical data from its Phase 3 HERO and open-label extension (OLE) trials for ARD-101. This strategic move aims to evaluate the drug's overall safety and efficacy profile and determine a path forward. This proactive engagement, combined with the company's strong financial position, reporting $91.2 million in cash, cash equivalents, and short-term investments as of fiscal Q1 2026 (ended March 31, 2026), which is projected to fund operations into mid-2027, provided investors with some reassurance regarding the company's resilience and ongoing commitment to its lead pipeline despite regulatory setbacks.
Show more
Aardvark Therapeutics (AARD) stock has gained about 100% since 3/31/2026 because of the following key factors:
1. Recovery from Heavily Oversold Conditions: Following substantial stock price declines, including a 56% drop in early March 2026 due to a voluntary pause of its lead ARD-101 Phase 3 trial and a further 32-34% plunge in mid-May 2026 after the U.S. Food and Drug Administration (FDA) issued a full clinical hold on ARD-101, Aardvark Therapeutics' shares likely became significantly oversold. This severe undervaluation attracted bargain hunters and prompted short covering, driving a sharp rebound from its low point around $3.59 in early June 2026 to approximately $7.60 by early July 2026.
2. Commitment to ARD-101 Program and Financial Stability: Despite the FDA clinical hold, Aardvark announced in mid-May 2026 its plans to unblind the accumulated clinical data from its Phase 3 HERO and open-label extension (OLE) trials for ARD-101. This strategic move aims to evaluate the drug's overall safety and efficacy profile and determine a path forward. This proactive engagement, combined with the company's strong financial position, reporting $91.2 million in cash, cash equivalents, and short-term investments as of fiscal Q1 2026 (ended March 31, 2026), which is projected to fund operations into mid-2027, provided investors with some reassurance regarding the company's resilience and ongoing commitment to its lead pipeline despite regulatory setbacks.
Show more
Updated on 7/12/2026
Aardvark Therapeutics (AARD) stock has gained about 100% since 3/31/2026 because of the following key factors:
1. Recovery from Heavily Oversold Conditions: Following substantial stock price declines, including a 56% drop in early March 2026 due to a voluntary pause of its lead ARD-101 Phase 3 trial and a further 32-34% plunge in mid-May 2026 after the U.S. Food and Drug Administration (FDA) issued a full clinical hold on ARD-101, Aardvark Therapeutics' shares likely became significantly oversold. This severe undervaluation attracted bargain hunters and prompted short covering, driving a sharp rebound from its low point around $3.59 in early June 2026 to approximately $7.60 by early July 2026.
2. Commitment to ARD-101 Program and Financial Stability: Despite the FDA clinical hold, Aardvark announced in mid-May 2026 its plans to unblind the accumulated clinical data from its Phase 3 HERO and open-label extension (OLE) trials for ARD-101. This strategic move aims to evaluate the drug's overall safety and efficacy profile and determine a path forward. This proactive engagement, combined with the company's strong financial position, reporting $91.2 million in cash, cash equivalents, and short-term investments as of fiscal Q1 2026 (ended March 31, 2026), which is projected to fund operations into mid-2027, provided investors with some reassurance regarding the company's resilience and ongoing commitment to its lead pipeline despite regulatory setbacks.
3. Underlying Therapeutic Potential and Pipeline Diversity: The earlier publication of positive Phase 2 proof-of-concept data for ARD-101 in the peer-reviewed journal Molecular Metabolism in March 2026, which demonstrated a significant reduction in self-reported hunger in patients with obesity, likely sustained some investor interest in the drug's underlying therapeutic potential. Although the ARD-201 program was also voluntarily paused, Aardvark's continued mention of ARD-201 and preclinical candidate WE-868 in its pipeline contributes to the perception of longer-term value, making the significantly discounted stock appealing to speculative investors anticipating future developments.
Show less
Aardvark Therapeutics (AARD) stock has gained about 100% since 3/31/2026 because of the following key factors:
1. Recovery from Heavily Oversold Conditions: Following substantial stock price declines, including a 56% drop in early March 2026 due to a voluntary pause of its lead ARD-101 Phase 3 trial and a further 32-34% plunge in mid-May 2026 after the U.S. Food and Drug Administration (FDA) issued a full clinical hold on ARD-101, Aardvark Therapeutics' shares likely became significantly oversold. This severe undervaluation attracted bargain hunters and prompted short covering, driving a sharp rebound from its low point around $3.59 in early June 2026 to approximately $7.60 by early July 2026.
2. Commitment to ARD-101 Program and Financial Stability: Despite the FDA clinical hold, Aardvark announced in mid-May 2026 its plans to unblind the accumulated clinical data from its Phase 3 HERO and open-label extension (OLE) trials for ARD-101. This strategic move aims to evaluate the drug's overall safety and efficacy profile and determine a path forward. This proactive engagement, combined with the company's strong financial position, reporting $91.2 million in cash, cash equivalents, and short-term investments as of fiscal Q1 2026 (ended March 31, 2026), which is projected to fund operations into mid-2027, provided investors with some reassurance regarding the company's resilience and ongoing commitment to its lead pipeline despite regulatory setbacks.
3. Underlying Therapeutic Potential and Pipeline Diversity: The earlier publication of positive Phase 2 proof-of-concept data for ARD-101 in the peer-reviewed journal Molecular Metabolism in March 2026, which demonstrated a significant reduction in self-reported hunger in patients with obesity, likely sustained some investor interest in the drug's underlying therapeutic potential. Although the ARD-201 program was also voluntarily paused, Aardvark's continued mention of ARD-201 and preclinical candidate WE-868 in its pipeline contributes to the perception of longer-term value, making the significantly discounted stock appealing to speculative investors anticipating future developments.
Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →
Stock Movement Drivers
Fundamental Drivers
The 101.9% change in AARD stock from 3/31/2026 to 7/12/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 3312026 | 7122026 | Change |
|---|---|---|---|
| Stock Price ($) | 3.77 | 7.61 | 101.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 22 | 22 | 0.0% |
| Cumulative Contribution | 0.0% |
Market Drivers
3/31/2026 to 7/12/2026| Return | Correlation | |
|---|---|---|
| AARD | 101.6% | |
| Market (SPY) | 16.1% | 30.4% |
| Sector (XLV) | 9.7% | 4.2% |
Fundamental Drivers
The -42.0% change in AARD stock from 12/31/2025 to 7/12/2026 was primarily driven by a -0.5% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 12312025 | 7122026 | Change |
|---|---|---|---|
| Stock Price ($) | 13.12 | 7.61 | -42.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 22 | 22 | -0.5% |
| Cumulative Contribution | 0.0% |
Market Drivers
12/31/2025 to 7/12/2026| Return | Correlation | |
|---|---|---|
| AARD | -42.1% | |
| Market (SPY) | 11.0% | 28.5% |
| Sector (XLV) | 4.3% | 15.4% |
Fundamental Drivers
The -43.7% change in AARD stock from 6/30/2025 to 7/12/2026 was primarily driven by a -40.8% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 6302025 | 7122026 | Change |
|---|---|---|---|
| Stock Price ($) | 13.52 | 7.61 | -43.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | � | 0 | 0.0% |
| P/S Multiple | � | ∞ | 0.0% |
| Shares Outstanding (Mil) | 13 | 22 | -40.8% |
| Cumulative Contribution | 0.0% |
Market Drivers
6/30/2025 to 7/12/2026| Return | Correlation | |
|---|---|---|
| AARD | -43.8% | |
| Market (SPY) | 23.2% | 26.0% |
| Sector (XLV) | 20.9% | 16.7% |
Fundamental Drivers
nullnull
Market Drivers
6/30/2023 to 7/12/2026| Return | Correlation | |
|---|---|---|
| AARD | ||
| Market (SPY) | 76.3% | 24.9% |
| Sector (XLV) | 26.9% | 21.1% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| AARD Return | - | - | - | - | -8% | -62% | -65% |
| Peers Return | -23% | 64% | 20% | 4% | 173% | 10% | 374% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 10% | 101% |
Monthly Win Rates [3] | |||||||
| AARD Win Rate | - | - | - | - | 36% | 29% | |
| Peers Win Rate | 40% | 53% | 47% | 43% | 52% | 49% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 57% | |
Max Drawdowns [4] | |||||||
| AARD Max Drawdown | - | - | - | - | - | -78% | |
| Peers Max Drawdown | -58% | -64% | -64% | -54% | -46% | -35% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: RYTM, VKTX, ALT, RLMD, HRMY.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 7/10/2026 (YTD)
How Low Can It Go
| Event | AARD | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -53.0% | -18.8% |
| % Gain to Breakeven | 112.9% | 23.1% |
| Time to Breakeven | 68 days | 79 days |
In The Past
Aardvark Therapeutics's stock fell -53.0% during the 2025 US Tariff Shock. Such a loss loss requires a 112.9% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | AARD | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -53.0% | -18.8% |
| % Gain to Breakeven | 112.9% | 23.1% |
| Time to Breakeven | 68 days | 79 days |
In The Past
Aardvark Therapeutics's stock fell -53.0% during the 2025 US Tariff Shock. Such a loss loss requires a 112.9% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Aardvark Therapeutics (AARD)
MB Financial, Inc. operates as a bank holding company for MB Financial Bank, N.A. that provides various financial services to small and middle market businesses, and individuals in the United States. The company's Banking segment offers commercial banking products, including working capital loans and lines of credit; accounts receivable financing; inventory and equipment financing; industrial revenue bond financing; ESOP financing; business acquisition loans; owner occupied real estate loans; asset-based loans; and financial, performance, and commercial letters of credit. Its commercial banking products also comprise deposit and treasury management products and services, such as Internet banking products, investment sweep and zero balance accounts, automated tax payments, ATM access, telephone banking, lockboxes, automated clearing house transactions, account reconciliation, controlled disbursement, information reporting, wire transfers, vault services, remote deposit capture, and checking accounts; capital markets and international banking services; and credit, deposit, and treasury management services for real estate operators and investors. In addition, this segment offers loans to equipment lessors; retail banking services; and wealth management solutions. The company's Leasing segment provides lease originations and related services. This segment's lease portfolio consists of computer systems, satellite equipment, and medical equipment, as well as general manufacturing, industrial, construction, and transportation equipment. Its Mortgage Banking segment originates and services residential mortgage loans for sale to investors. The company offers its products and services through 95 banking offices in the Chicago metropolitan area; 1 banking office in Philadelphia, Pennsylvania; and 140 ATMs. MB Financial, Inc. was founded in 1911 and is headquartered in Chicago, Illinois.
AI Analysis | Feedback
null
AI Analysis | Feedback
- Commercial Banking Services: Provides working capital loans, lines of credit, equipment financing, and other specialized lending products for businesses.
- Deposit and Treasury Management: Offers checking accounts, internet banking, payment processing, and cash management solutions for commercial clients.
- Retail Banking: Delivers general banking services to individual customers.
- Wealth Management: Provides financial planning and investment advisory services.
- Equipment Leasing: Originates and manages leases for a diverse range of equipment, including computer systems and industrial machinery.
- Mortgage Banking: Specializes in originating and servicing residential mortgage loans for sale to investors.
- Real Estate Financing and Services: Offers loans, deposit services, and treasury management solutions specifically for real estate operators and investors.
AI Analysis | Feedback
null
AI Analysis | Feedback
null
AI Analysis | Feedback
null
AI Analysis | Feedback
null
AI Analysis | Feedback
null
AI Analysis | Feedback
Aardvark Therapeutics (AARD) is a clinical-stage biopharmaceutical company primarily focused on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases.
The company's main product candidate, ARD-101, is an oral investigational drug in Phase 3 clinical development for the treatment of hyperphagia associated with Prader-Willi Syndrome (PWS).
Addressable Markets:
- ARD-101 for Prader-Willi Syndrome (PWS): The global market for Prader-Willi Syndrome treatment is estimated to be USD 0.98 billion in 2025 and is projected to reach USD 1.59 billion by 2032, growing at a compound annual growth rate (CAGR) of 7.2%. Another estimate values the global market at USD 599.81 million in 2023, expected to reach USD 1,131.94 million by 2033, with a CAGR of approximately 6.56%. In the U.S. alone, there are an estimated 10,000 to 20,000 individuals with Prader-Willi.
- ARD-201 for Obesity and obesity-related conditions: Aardvark Therapeutics is also developing ARD-201, a planned fixed-dose combination of ARD-101 with a DPP-4 inhibitor, for obesity and obesity-related conditions. Specific addressable market sizes in dollar amounts for this product were not available in the provided information.
AI Analysis | Feedback
null
AI Analysis | Feedback
null
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Aardvark Therapeutics Earnings Notes | 12/16/2025 |
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 21.87 |
| Mkt Cap | 1.3 |
| Rev LTM | 0 |
| Op Inc LTM | -86 |
| FCF LTM | -67 |
| FCF 3Y Avg | -75 |
| CFO LTM | -67 |
| CFO 3Y Avg | -75 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 58.7% |
| Rev Chg 3Y Avg | 93.7% |
| Rev Chg Q | 16.6% |
| QoQ Delta Rev Chg LTM | 3.5% |
| Op Inc Chg LTM | -8.6% |
| Op Inc Chg 3Y Avg | -2.7% |
| Op Mgn LTM | -90.9% |
| Op Mgn 3Y Avg | -170.9% |
| QoQ Delta Op Mgn LTM | -2.9% |
| CFO/Rev LTM | -55.0% |
| CFO/Rev 3Y Avg | -96.9% |
| FCF/Rev LTM | -55.0% |
| FCF/Rev 3Y Avg | -113.4% |
Segment Financials
Revenue by Segment| $ Mil | 2023 | 2022 |
|---|---|---|
| Discovery and development of novel therapies for the treatment of metabolic diseases | 0 | 0 |
| Total | 0 | 0 |
| $ Mil | 2025 | 2024 | 2023 |
|---|---|---|---|
| Discovery and development of novel therapies for the treatment of metabolic diseases | -58 | -21 | -7 |
| Total | -58 | -21 | -7 |
| $ Mil | 2023 | 2022 |
|---|---|---|
| Discovery and development of novel therapies for the treatment of metabolic diseases | 11 | 17 |
| Total | 11 | 17 |
Price Behavior
Price Behavior
| Market Price | $7.60 | |
| Market Cap ($ Bil) | 0.2 | |
| First Trading Date | 12/29/2006 | |
| Distance from 52W High | -56.3% | |
| 50 Days | 200 Days | |
| DMA Price | $4.87 | $11.84 |
| DMA Trend | down | indeterminate |
| Distance from DMA | 56.0% | -35.8% |
| 3M | 1YR | |
| Volatility | 151.5% | 122.0% |
| Downside Capture | 435.29 | 389.06 |
| Upside Capture | 522.65 | 245.59 |
| Correlation (SPY) | 44.1% | 27.8% |
AARD Betas & Captures as of 6/30/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 2.21 | 3.25 | 2.72 | 2.73 | 2.38 | -0.05 |
| Up Beta | 2.21 | 1.91 | 1.14 | 3.65 | 1.49 | 0.54 |
| Down Beta | 4.62 | 4.29 | 4.17 | 2.30 | 1.77 | -0.65 |
| Up Capture | 412% | 396% | 460% | 119% | 306% | 79% |
| Bmk +ve Days | 11 | 24 | 40 | 67 | 140 | 429 |
| Stock +ve Days | 11 | 22 | 36 | 66 | 129 | 177 |
| Down Capture | -36% | 322% | 307% | 237% | 192% | 109% |
| Bmk -ve Days | 10 | 17 | 23 | 58 | 112 | 321 |
| Stock -ve Days | 10 | 19 | 27 | 59 | 122 | 165 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with AARD | |
|---|---|---|---|---|
| AARD | -40.4% | 121.4% | 0.21 | - |
| Sector ETF (XLV) | 20.3% | 15.7% | 0.98 | 17.1% |
| Equity (SPY) | 22.1% | 12.5% | 1.31 | 26.4% |
| Gold (GLD) | 23.5% | 27.8% | 0.75 | 8.2% |
| Commodities (DBC) | 23.6% | 18.7% | 0.99 | -11.2% |
| Real Estate (VNQ) | 13.4% | 13.9% | 0.67 | 13.7% |
| Bitcoin (BTCUSD) | -42.5% | 42.8% | -1.17 | 14.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with AARD | |
|---|---|---|---|---|
| AARD | -12.4% | 121.9% | 0.22 | - |
| Sector ETF (XLV) | 6.5% | 14.9% | 0.25 | 21.2% |
| Equity (SPY) | 13.4% | 17.1% | 0.61 | 25.0% |
| Gold (GLD) | 17.8% | 18.3% | 0.79 | 5.6% |
| Commodities (DBC) | 7.3% | 19.5% | 0.27 | -7.5% |
| Real Estate (VNQ) | 2.9% | 18.9% | 0.05 | 20.4% |
| Bitcoin (BTCUSD) | 13.8% | 53.4% | 0.44 | 14.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with AARD | |
|---|---|---|---|---|
| AARD | -6.4% | 121.9% | 0.22 | - |
| Sector ETF (XLV) | 10.3% | 16.6% | 0.51 | 21.2% |
| Equity (SPY) | 15.6% | 17.9% | 0.75 | 25.0% |
| Gold (GLD) | 11.6% | 16.1% | 0.59 | 5.6% |
| Commodities (DBC) | 6.0% | 18.0% | 0.26 | -7.5% |
| Real Estate (VNQ) | 5.1% | 20.7% | 0.21 | 20.4% |
| Bitcoin (BTCUSD) | 58.6% | 66.2% | 0.99 | 14.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Updated 6/12/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 5/7/2026 | -4.9% | 11.9% | -37.5% |
| 11/13/2025 | -8.7% | -13.2% | 28.2% |
| 8/13/2025 | 0.5% | -13.7% | -23.3% |
| 5/14/2025 | 4.0% | 27.2% | 22.9% |
| SUMMARY STATS | |||
| # Positive | 2 | 2 | 2 |
| # Negative | 2 | 2 | 2 |
| Median Positive | 2.3% | 19.6% | 25.5% |
| Median Negative | -6.8% | -13.4% | -30.4% |
| Max Positive | 4.0% | 27.2% | 28.2% |
| Max Negative | -8.7% | -13.7% | -37.5% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 5/7/2026 | -4.9% | 11.9% | -37.5% |
| 11/13/2025 | -8.7% | -13.2% | 28.2% |
| 8/13/2025 | 0.5% | -13.7% | -23.3% |
| 5/14/2025 | 4.0% | 27.2% | 22.9% |
| SUMMARY STATS | |||
| # Positive | 2 | 2 | 2 |
| # Negative | 2 | 2 | 2 |
| Median Positive | 2.3% | 19.6% | 25.5% |
| Median Negative | -6.8% | -13.4% | -30.4% |
| Max Positive | 4.0% | 27.2% | 28.2% |
| Max Negative | -8.7% | -13.7% | -37.5% |
Recent Forward Guidance
Updated 7/12/2026Latest: Q1 2026 Earnings Reported 5/7/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2027 Cash Runway | 2,028 | 0.0% | Raised | Guidance: 2,027 for 2027 | |||
Prior: Q3 2025 Earnings Reported 11/13/2025
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2027 Cash Runway | 2,027 | 0 | Affirmed | Guidance: 2,027 for 2027 | |||
Insider Activity
Updated 4/26/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Sun, Nelson | Chief Financial Officer | Direct | Buy | 12122025 | 14.40 | 3,000 | 43,200 | 1,562,170 | Form |
| 2 | Lee, Tien-Li | Chief Executive Officer | Direct | Buy | 12122025 | 14.48 | 7,000 | 101,395 | 22,475,114 | Form |
| 3 | Lee, Tien-Li | Chief Executive Officer | Direct | Buy | 9162025 | 9.66 | 10,000 | 96,624 | 14,912,732 | Form |
| 4 | Lee, Tien-Li | Chief Executive Officer | Direct | Buy | 9122025 | 8.50 | 5,000 | 42,516 | 13,038,517 | Form |
| 5 | Lee, Tien-Li | Chief Executive Officer | Direct | Buy | 9122025 | 7.82 | 6,000 | 46,926 | 11,953,491 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Sun, Nelson | Chief Financial Officer | Direct | Buy | 12122025 | 14.40 | 3,000 | 43,200 | 1,562,170 | Form |
| 2 | Lee, Tien-Li | Chief Executive Officer | Direct | Buy | 12122025 | 14.48 | 7,000 | 101,395 | 22,475,114 | Form |
| 3 | Lee, Tien-Li | Chief Executive Officer | Direct | Buy | 9162025 | 9.66 | 10,000 | 96,624 | 14,912,732 | Form |
| 4 | Lee, Tien-Li | Chief Executive Officer | Direct | Buy | 9122025 | 8.50 | 5,000 | 42,516 | 13,038,517 | Form |
| 5 | Lee, Tien-Li | Chief Executive Officer | Direct | Buy | 9122025 | 7.82 | 6,000 | 46,926 | 11,953,491 | Form |
| 6 | Lee, Tien-Li | Chief Executive Officer | Direct | Buy | 9122025 | 7.91 | 9,000 | 71,212 | 12,045,863 | Form |
| 7 | Sun, Nelson | Chief Financial Officer | Direct | Buy | 9102025 | 8.07 | 6,000 | 48,440 | 851,604 | Form |
Investor Activity (13F)
Updated Jul 12, 202613F holdings as of Mar 31, 2026 (Q1 2026)
Active managers (13F portfolio over $250M, at least 3 holdings) with a position over $5M that is either over 10% of their portfolio or held in a concentrated book of 50 or fewer total positions. Index/ETF, sovereign, bank and community-bank filers are excluded.
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.
Core Cache Last Updated: 7/12/2026